Tag: Immunoglobulin Market – Global Immunoglobulin Industry Size

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Anti-D Immunoglobulin Market Size, Value And Growth Trajectory Through 2030

The anti-d immunoglobulin market has shown substantial expansion in recent years. Its valuation is anticipated to rise from $2.59 billion in 2025 to $2.76 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.6%. Over the historical period, this growth can be ascribed to a number of factors including limited plasma donor pools, reliance on manual antibody extraction processes, increasing awareness of hemolytic disease, expanding usage in hospitals and clinical settings, and the adoption of intramuscular administration.

The anti-d immunoglobulin market is projected to show significant expansion in the upcoming years. It is forecast to reach $3.55 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast period can be attributed to the development of intravenous formulations, the wider adoption of automated plasma fractionation technologies, a rise in antenatal screening programs, the increasing global blood bank infrastructure, and the expansion of personalized immunoglobulin therapies. Prominent trends for this period include a growing demand for anti-d immunoglobulin in the management of hemolytic disease, an increased preference for pre-filled syringes and single-use vials, the broadening of antenatal and postnatal prophylaxis programs, the growth of distribution channels based in hospitals and blood banks, and an enhanced focus on ensuring safety, purity, and regulatory compliance.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25694&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Anti-D Immunoglobulin Market Growth Factors Behind Sustained Expansion

The anti-D immunoglobulin market is projected to expand driven by increasing birth rates. These rates, defined as annual live births per 1,000 individuals, are rising partly due to limited access to education and family planning, leading to higher fertility and larger family sizes. Anti-D immunoglobulin plays a crucial role by mitigating Rh incompatibility during pregnancy, thereby lowering the risk of hemolytic disease in newborns and fostering healthier subsequent pregnancies. For example, data from the US-based Centers for Disease Control and Prevention indicated 3,622,673 births in 2024, a 1% rise from the previous year, highlighting this trend. Consequently, elevated birth rates are a key factor boosting the anti-D immunoglobulin market.

Anti-D Immunoglobulin Market Driver: Expansion Of Healthcare Infrastructure Fueling The Growth Of The Market Due To Improved Access To Maternal Care Services

The anti-D immunoglobulin market is set to grow as healthcare infrastructure continues to expand. This infrastructure, encompassing facilities, equipment, personnel, and support systems for medical services, is developing in response to increasing global populations, which in turn elevates the demand for healthcare and necessitates more hospitals, clinics, and related resources. Such expansion improves access to maternal care, facilitating superior screening and prompt administration of anti-D immunoglobulin to avert hemolytic disease in newborns. For instance, in May 2023, the UK’s Department of Health and Social Care declared plans to invest over $27 billion (£20 billion) in new hospital construction, with two hospitals already finished, five underway, and over 20 projected to be in progress or completed by the end of 2023 under the New Hospital Programme. This expansion of healthcare infrastructure is thus a key driver for the anti-D immunoglobulin market.

Anti-D Immunoglobulin Market Segment Landscape And Growth Outlook

The anti-d immunoglobulin market covered in this report is segmented –

1) By Product Type: Intramuscular Anti-D Immunoglobulin, Intravenous Anti-D Immunoglobulin

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel

3) By Application: Hemolytic Disease Of The Newborn, Immune Thrombocytopenic Purpura, Antenatal And Postnatal Prophylaxis, Other Applications

4) By End-User: Hospitals, Clinics, Blood Banks, Research Laboratories

Subsegments:

1) By Intramuscular Anti-D Immunoglobulin: Standard Dose, High Dose, Pre-Filled Syringes, Vials

2) By Intravenous Anti-D Immunoglobulin: Lyophilized Powder, Liquid Formulation, Single-Use Vials, Multi-Dose Vials

Anti-D Immunoglobulin Market Competitive Landscape: Who Leads The Industry?

Major companies operating in the anti-d immunoglobulin market are CSL Behring, Octapharma AG, Kedrion Biopharma Inc., Biotest AG, Sanquin, Bharat Serums and Vaccines Limited, Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Emergent BioSolutions Inc., Kamada Pharmaceuticals, Saol Therapeutics Inc., Avin Darou, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Taj Pharmaceuticals Limited, Aetos Pharma Private Limited, PV Pharma Healthcare Pvt. Ltd., Grifols S.A., Takeda Pharmaceutical Company Limited, LFB Biomedicaments, China Biologic Products Holdings Inc., Shanghai RAAS Blood Products Co. Ltd., Hualan Biological Engineering Inc., CBPO (Shandong Taibang Biological Products Co. Ltd.), Bio Products Laboratory (BPL), Instituto Grifols S.A., HemaCare Corporation, KM Biologics Co. Ltd., National Bioproducts Institute (NBI), GC Pharma (Green Cross Corporation), SK Plasma Co. Ltd.

View The Full Anti-D Immunoglobulin Market Report:

https://www.thebusinessresearchcompany.com/report/anti-d-immunoglobulin-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Anti-D Immunoglobulin Market Largest Region: Which Geography Holds The Biggest Share?

North America was the largest region in the anti-D immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-d immunoglobulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Anti-D Immunoglobulin Market Expansion Outlook: What Revenue Opportunities Lie Ahead?

The anti-D immunoglobulin market has experienced robust growth over the past few years, with projections indicating an increase from $2.59 billion in 2025 to $2.76 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.6%. This expansion during the historical period has been driven by several key factors, including the limited availability of plasma donors, the dependence on manual methods for antibody extraction, a heightened understanding of hemolytic disease, growing utilization in hospitals and clinical settings, and the widespread adoption of intramuscular administration techniques.

The anti-D immunoglobulin market is projected to experience robust growth over the coming years, with expectations of reaching $3.55 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.5%. This anticipated expansion during the forecast period is driven by several key factors, including the development of intravenous formulations, the advancement of automated plasma fractionation technologies, an uptick in antenatal screening initiatives, the strengthening of global blood bank infrastructure, and the growth of personalized immunoglobulin therapies. Notable trends shaping this phase include a heightened demand for anti-D immunoglobulin in the management of hemolytic disease, a greater adoption of pre-filled syringes and single-use vials, the expansion of both antenatal and postnatal prophylaxis programs, a rise in distribution channels through hospitals and blood banks, and an amplified focus on safety, purity, and regulatory adherence.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25694&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Anti-D Immunoglobulin Market Industry Drivers: What Is Driving Revenue Growth?

The anticipated increase in birth rates is expected to drive future growth in the anti-D immunoglobulin market. Birth rates, defined as the number of live births recorded per 1,000 individuals in a population each year, are rising due to limited access to education and family planning services, which leads to higher fertility rates and larger families. This immunoglobulin assists in managing birth rates by preventing Rh incompatibility during pregnancy, thereby lowering the likelihood of hemolytic disease in newborns and promoting improved outcomes in subsequent pregnancies. As an example, the Centers for Disease Control and Prevention, a US government agency, reported in April 2025 that there were 3,622,673 births in 2024, marking a 1% rise from 2023. Consequently, elevated birth rates are fueling the expansion of the anti-D immunoglobulin market.

Anti-D Immunoglobulin Market Driver: Expansion Of Healthcare Infrastructure Fueling The Growth Of The Market Due To Improved Access To Maternal Care Services

Future growth in the anti-D immunoglobulin market is anticipated to be driven by the ongoing expansion of healthcare infrastructure. This term encompasses the network of facilities, equipment, personnel, and support systems required to deliver medical services to a population. The expansion is being spurred by a growing global population, which increases the demand for medical care and necessitates more hospitals, clinics, and related resources. Enhanced healthcare infrastructure improves access to maternal care, facilitating better screening and the timely administration of anti-D immunoglobulin to prevent hemolytic disease in newborns. For instance, in May 2023, the Department of Health and Social Care, a UK government department, declared plans to allocate over $27 billion (£20 billion) for constructing new hospital facilities. Under the New Hospital Programme, two hospitals have been completed, five are under construction, and more than 20 are scheduled to begin or finish by the end of 2023. Thus, the broadening healthcare infrastructure is propelling the anti-D immunoglobulin market forward.

Anti-D Immunoglobulin Market Driver: Expansion Of Prenatal And Antenatal Screening Programs Fueling The Growth Of The Market Due To Improved Maternal-Fetal Risk Management

The growth of the anti-D immunoglobulin market is expected to be propelled by the expansion of prenatal and antenatal screening programs moving forward. These screening programs involve testing pregnant women for blood group compatibility and fetal RhD genotype to prevent hemolytic disease in the fetus and newborn. Their expansion is being driven by the adoption of noninvasive prenatal testing (NIPT) using cell-free fetal DNA, which enables precise determination of fetal RhD status. Such programs support the effective use of anti-D immunoglobulin by identifying Rh-negative mothers early in pregnancy, monitoring for potential sensitization events, and ensuring timely intervention to prevent Rh incompatibility, thereby safeguarding both maternal and fetal health. As a case in point, the World Health Organization (WHO), a Switzerland-based international public health agency, estimated in July 2025 that around 1.2 million pregnant women were living with HIV in 2023, with approximately 84% receiving antiretroviral medicines to prevent mother-to-child transmission. Therefore, the widening of prenatal and antenatal screening initiatives is driving the anti-D immunoglobulin market’s growth.

Anti-D Immunoglobulin Market Segment Performance And Strategic Opportunities

The anti-d immunoglobulin market covered in this report is segmented –

1) By Product Type: Intramuscular Anti-D Immunoglobulin, Intravenous Anti-D Immunoglobulin

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel

3) By Application: Hemolytic Disease Of The Newborn, Immune Thrombocytopenic Purpura, Antenatal And Postnatal Prophylaxis, Other Applications

4) By End-User: Hospitals, Clinics, Blood Banks, Research Laboratories

Subsegments:

1) By Intramuscular Anti-D Immunoglobulin: Standard Dose, High Dose, Pre-Filled Syringes, Vials

2) By Intravenous Anti-D Immunoglobulin: Lyophilized Powder, Liquid Formulation, Single-Use Vials, Multi-Dose Vials

Anti-D Immunoglobulin Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the anti-d immunoglobulin market are CSL Behring, Octapharma AG, Kedrion Biopharma Inc., Biotest AG, Sanquin, Bharat Serums and Vaccines Limited, Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Emergent BioSolutions Inc., Kamada Pharmaceuticals, Saol Therapeutics Inc., Avin Darou, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Taj Pharmaceuticals Limited, Aetos Pharma Private Limited, PV Pharma Healthcare Pvt. Ltd., Grifols S.A., Takeda Pharmaceutical Company Limited, LFB Biomedicaments, China Biologic Products Holdings Inc., Shanghai RAAS Blood Products Co. Ltd., Hualan Biological Engineering Inc., CBPO (Shandong Taibang Biological Products Co. Ltd.), Bio Products Laboratory (BPL), Instituto Grifols S.A., HemaCare Corporation, KM Biologics Co. Ltd., National Bioproducts Institute (NBI), GC Pharma (Green Cross Corporation), SK Plasma Co. Ltd.

Access The Complete Anti-D Immunoglobulin Market Report:

https://www.thebusinessresearchcompany.com/report/anti-d-immunoglobulin-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Anti-D Immunoglobulin Market Largest Region By Revenue And Market Share

North America was the largest region in the anti-D immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-d immunoglobulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Anti-D Immunoglobulin Market In 2026 And 2030?

The anti-d immunoglobulin market has witnessed significant growth in recent years. It is projected to increase from $2.59 billion in 2025 to $2.76 billion in 2026, at a compound annual growth rate (CAGR) of 6.6%. The expansion observed in the historic period stemmed from factors including limited plasma donor pools, the use of manual antibody extraction processes, heightened awareness of hemolytic disease, greater hospital and clinical usage, and the adoption of intramuscular administration.

The anti-d immunoglobulin market is projected to experience robust expansion in the coming years, anticipated to reach a valuation of $3.55 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. Factors contributing to this growth during the forecast period include the advancement of intravenous formulations, wider adoption of automated plasma fractionation technologies, an increase in antenatal screening initiatives, the expanding global blood bank infrastructure, and the rise of personalized immunoglobulin therapies. Key trends foreseen for this period encompass a growing need for anti-d immunoglobulin in managing hemolytic disease, greater uptake of pre-filled syringes and single-use vials, the extension of antenatal and postnatal prophylaxis schemes, the development of distribution channels centered in hospitals and blood banks, and a heightened emphasis on ensuring safety, purity, and adherence to regulations.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25694&type=smp

Which Important Drivers Are Guiding The Anti-D Immunoglobulin Market Growth?

The anti-D immunoglobulin market is projected to expand due to increasing birth rates, which represent the annual count of live births per 1,000 individuals within a population. These rates are rising because of limited access to education and family planning services, leading to higher fertility and larger families. Anti-D immunoglobulin supports birth rates by preventing Rh incompatibility during pregnancy, thereby minimizing the risk of hemolytic disease in newborns and promoting healthier outcomes in subsequent pregnancies. For instance, in April 2025, the US-based Centers for Disease Control and Prevention reported 3,622,673 recorded births in 2024, marking a 1% increase from 2023. Consequently, the high birth rates are a key factor driving the growth of the anti-D immunoglobulin market.

What Are The Main Segments Within The Anti-D Immunoglobulin Market Segment Structure?

The anti-d immunoglobulin market covered in this report is segmented –

1) By Product Type: Intramuscular Anti-D Immunoglobulin, Intravenous Anti-D Immunoglobulin

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel

3) By Application: Hemolytic Disease Of The Newborn, Immune Thrombocytopenic Purpura, Antenatal And Postnatal Prophylaxis, Other Applications

4) By End-User: Hospitals, Clinics, Blood Banks, Research Laboratories

Subsegments:

1) By Intramuscular Anti-D Immunoglobulin: Standard Dose, High Dose, Pre-Filled Syringes, Vials

2) By Intravenous Anti-D Immunoglobulin: Lyophilized Powder, Liquid Formulation, Single-Use Vials, Multi-Dose Vials

Who Are The Companies Participating In The Anti-D Immunoglobulin Market?

Major companies operating in the anti-d immunoglobulin market are CSL Behring, Octapharma AG, Kedrion Biopharma Inc., Biotest AG, Sanquin, Bharat Serums and Vaccines Limited, Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Emergent BioSolutions Inc., Kamada Pharmaceuticals, Saol Therapeutics Inc., Avin Darou, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Taj Pharmaceuticals Limited, Aetos Pharma Private Limited, PV Pharma Healthcare Pvt. Ltd., Grifols S.A., Takeda Pharmaceutical Company Limited, LFB Biomedicaments, China Biologic Products Holdings Inc., Shanghai RAAS Blood Products Co. Ltd., Hualan Biological Engineering Inc., CBPO (Shandong Taibang Biological Products Co. Ltd.), Bio Products Laboratory (BPL), Instituto Grifols S.A., HemaCare Corporation, KM Biologics Co. Ltd., National Bioproducts Institute (NBI), GC Pharma (Green Cross Corporation), SK Plasma Co. Ltd.

Get The Full Anti-D Immunoglobulin Market Report:

https://www.thebusinessresearchcompany.com/report/anti-d-immunoglobulin-global-market-report

Which Region Represents The Largest Share Of The Anti-D Immunoglobulin Market?

North America was the largest region in the anti-D immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-d immunoglobulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Anti-D Immunoglobulin Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/anti-d-immunoglobulin-global-market-report

Browse Through More Reports Similar to the Global Anti-D Immunoglobulin Market 2026, By The Business Research Company

Immunoglobulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Intravenous Immunoglobulin Market Report 2026

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Immunoassay Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Anti-D Immunoglobulin Market In 2026 And What Value Is Projected For 2030?

The anti-d immunoglobulin market size has seen substantial growth over recent years. It is anticipated to increase from $2.59 billion in 2025 to $2.76 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.6%. The expansion observed in previous periods was driven by factors such as restricted plasma donor pools, reliance on manual antibody extraction procedures, heightened awareness of hemolytic disease, expanded hospital and clinical utilization, and the adoption of intramuscular administration.

The anti-d immunoglobulin market is projected to experience robust expansion over the coming years. This market is forecast to reach $3.55 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. Factors contributing to this growth during the forecast period include the advancement of intravenous formulations, the spread of automated plasma fractionation technologies, an increase in antenatal screening initiatives, the growing global blood bank infrastructure, and the development of personalized immunoglobulin therapies. Key trends anticipated during the forecast timeframe encompass a surging need for anti-d immunoglobulin in managing hemolytic disease, greater uptake of pre-filled syringes and single-use vials, the broadening of antenatal and postnatal prophylaxis schemes, the expansion of hospital and blood bank distribution routes, and an increased emphasis on safety, purity, and adherence to regulations.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25694&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Anti-D Immunoglobulin Market?

The anticipated high birth rates are projected to stimulate the growth of the anti-D immunoglobulin market moving forward. Birth rates signify the yearly count of live births per 1,000 individuals within a population. These rates are rising because of limited access to educational resources and family planning services, which in turn leads to greater fertility and larger families. Anti-D immunoglobulin aids in managing birth rates by preventing Rh incompatibility during pregnancy, thereby decreasing the likelihood of hemolytic disease in newborns and promoting healthier outcomes for subsequent pregnancies. As an illustration, the Centers for Disease Control and Prevention, a US government agency, reported in April 2025 that 3,622,673 births were recorded in 2024, representing a 1% increase compared to 2023. Consequently, the elevated birth rates are a key factor driving the expansion of the anti-D immunoglobulin market. The expansion of healthcare infrastructure is set to accelerate the growth of the anti-D immunoglobulin market moving forward. Healthcare infrastructure encompasses the comprehensive system of facilities, necessary equipment, skilled workforce, and support mechanisms vital for delivering health services to a community. This infrastructure is growing as a direct result of the increasing global population, which in turn escalates the demand for medical care and necessitates the establishment of more hospitals, clinics, and related resources. Enhancements in healthcare infrastructure improve access to maternal healthcare, which allows for better screening processes and the timely administration of anti-D immunoglobulin to avert hemolytic disease in infants. For example, in May 2023, the Department of Health and Social Care, a government body in the UK, revealed plans to invest over $27 billion (£20 billion) in constructing new hospital facilities. Under the New Hospital Programme, two hospitals are already complete, five are currently under construction, and more than 20 are projected to be initiated or finalized by the close of 2023. Therefore, the expanding healthcare infrastructure is a significant impetus behind the growth of the anti-D immunoglobulin market.

What Are The Key Segments Of The Anti-D Immunoglobulin Market?

The anti-d immunoglobulin market covered in this report is segmented –

1) By Product Type: Intramuscular Anti-D Immunoglobulin, Intravenous Anti-D Immunoglobulin

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel

3) By Application: Hemolytic Disease Of The Newborn, Immune Thrombocytopenic Purpura, Antenatal And Postnatal Prophylaxis, Other Applications

4) By End-User: Hospitals, Clinics, Blood Banks, Research Laboratories

Subsegments:

1) By Intramuscular Anti-D Immunoglobulin: Standard Dose, High Dose, Pre-Filled Syringes, Vials

2) By Intravenous Anti-D Immunoglobulin: Lyophilized Powder, Liquid Formulation, Single-Use Vials, Multi-Dose Vials

Who Are The Leading Companies Operating In The Anti-D Immunoglobulin Market?

Major companies operating in the anti-d immunoglobulin market are CSL Behring, Octapharma AG, Kedrion Biopharma Inc., Biotest AG, Sanquin, Bharat Serums and Vaccines Limited, Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Emergent BioSolutions Inc., Kamada Pharmaceuticals, Saol Therapeutics Inc., Avin Darou, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Taj Pharmaceuticals Limited, Aetos Pharma Private Limited, PV Pharma Healthcare Pvt. Ltd., Grifols S.A., Takeda Pharmaceutical Company Limited, LFB Biomedicaments, China Biologic Products Holdings Inc., Shanghai RAAS Blood Products Co. Ltd., Hualan Biological Engineering Inc., CBPO (Shandong Taibang Biological Products Co. Ltd.), Bio Products Laboratory (BPL), Instituto Grifols S.A., HemaCare Corporation, KM Biologics Co. Ltd., National Bioproducts Institute (NBI), GC Pharma (Green Cross Corporation), SK Plasma Co. Ltd.

Read the full anti-d immunoglobulin market report here:

https://www.thebusinessresearchcompany.com/report/anti-d-immunoglobulin-global-market-report

What Are The Leading Geographic Regions In The Anti-D Immunoglobulin Market?

North America was the largest region in the anti-D immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-d immunoglobulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Anti-D Immunoglobulin Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25694&type=smp

Browse Through More Reports Similar to the Global Anti-D Immunoglobulin Market 2026, By The Business Research Company

Immunoglobulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Intravenous Immunoglobulin Market Report 2026

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Immunoassay Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the anti-d immunoglobulin market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Anti-D Immunoglobulin Market?

The anti-d immunoglobulin market size has demonstrated significant expansion in recent years. It is projected to climb from $2.59 billion in 2025 to $2.76 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.6%. The market’s historical growth can be attributed to factors like restricted plasma donor availability, dependence on manual antibody extraction processes, heightened awareness of hemolytic disease, increased utilization in hospitals and clinics, and the shift towards intramuscular administration.

The anti-d immunoglobulin market is projected to experience substantial expansion over the upcoming years, reaching a valuation of $3.55 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. This projected growth throughout the forecast period stems from factors such as advancements in intravenous formulations, the proliferation of automated plasma fractionation technologies, an increase in antenatal screening initiatives, improvements in the worldwide blood bank infrastructure, and the expansion of personalized immunoglobulin therapies. Key trends anticipated during this period encompass a heightened need for anti-d immunoglobulin in managing hemolytic disease, a greater uptake of pre-filled syringes and single-use vials, the broadening of antenatal and postnatal prophylaxis programs, an increase in distribution through hospital and blood bank networks, and a reinforced emphasis on ensuring safety, purity, and adherence to regulations.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25694&type=smp

Which Drivers Are Supporting The Rise Of The Anti-D Immunoglobulin Market?

The high birth rates are projected to fuel the expansion of the anti-D immunoglobulin market. Birth rates signify the annual count of live births per 1,000 individuals within a population. These rates are rising due to insufficient access to education and family planning resources, leading to increased fertility and larger families. Anti-D immunoglobulin aids in managing birth rates by preventing Rh incompatibility during pregnancy, thereby lessening the risk of hemolytic disease in newborns and promoting healthier outcomes in subsequent pregnancies. For instance, in April 2025, the Centers for Disease Control and Prevention, a US government body, reported 3,622,673 births in 2024, marking a 1% increase from 2023. Consequently, elevated birth rates are stimulating growth in the anti-D immunoglobulin market. The anti-D immunoglobulin market is anticipated to grow with the ongoing expansion of healthcare infrastructure. Healthcare infrastructure encompasses the essential facilities, equipment, workforce, and support systems required for delivering medical services to a population. This infrastructure is expanding due to the increasing global population, which drives higher demand for healthcare and necessitates the development of more hospitals, clinics, and related resources. Such expansion improves access to maternal healthcare, facilitating better screening and the timely administration of anti-D immunoglobulin to prevent hemolytic disease in newborns. For example, in May 2023, the UK’s Department of Health and Social Care announced plans to invest over $27 billion (£20 billion) in new hospital facilities. Under the New Hospital Programme, two hospitals have been completed, five are under construction, and more than 20 are expected to be initiated or finalized by the close of 2023. Therefore, the expanding healthcare infrastructure is a key driver for the anti-D immunoglobulin market.

What Segments Are Identified Within The Structure Of The Anti-D Immunoglobulin Market?

The anti-d immunoglobulin market covered in this report is segmented –

1) By Product Type: Intramuscular Anti-D Immunoglobulin, Intravenous Anti-D Immunoglobulin

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel

3) By Application: Hemolytic Disease Of The Newborn, Immune Thrombocytopenic Purpura, Antenatal And Postnatal Prophylaxis, Other Applications

4) By End-User: Hospitals, Clinics, Blood Banks, Research Laboratories

Subsegments:

1) By Intramuscular Anti-D Immunoglobulin: Standard Dose, High Dose, Pre-Filled Syringes, Vials

2) By Intravenous Anti-D Immunoglobulin: Lyophilized Powder, Liquid Formulation, Single-Use Vials, Multi-Dose Vials

Which Key Market Players Are Investing In Expansion And Innovation Within The Anti-D Immunoglobulin Market?

Major companies operating in the anti-d immunoglobulin market are CSL Behring, Octapharma AG, Kedrion Biopharma Inc., Biotest AG, Sanquin, Bharat Serums and Vaccines Limited, Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Emergent BioSolutions Inc., Kamada Pharmaceuticals, Saol Therapeutics Inc., Avin Darou, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Taj Pharmaceuticals Limited, Aetos Pharma Private Limited, PV Pharma Healthcare Pvt. Ltd., Grifols S.A., Takeda Pharmaceutical Company Limited, LFB Biomedicaments, China Biologic Products Holdings Inc., Shanghai RAAS Blood Products Co. Ltd., Hualan Biological Engineering Inc., CBPO (Shandong Taibang Biological Products Co. Ltd.), Bio Products Laboratory (BPL), Instituto Grifols S.A., HemaCare Corporation, KM Biologics Co. Ltd., National Bioproducts Institute (NBI), GC Pharma (Green Cross Corporation), SK Plasma Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/anti-d-immunoglobulin-global-market-report

Which Regions Are Poised For Strategic Growth In The Anti-D Immunoglobulin Market?

North America was the largest region in the anti-D immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-d immunoglobulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Anti-D Immunoglobulin Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25694&type=smp

Browse Through More Reports Similar to the Global Anti-D Immunoglobulin Market 2026, By The Business Research Company

Immunoglobulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Intravenous Immunoglobulin Market Report 2026

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Immunoassay Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What CAGR And Valuation Are Anticipated For The Anti-D Immunoglobulin Market?

Recent years have seen a substantial upswing in the size of the anti-D immunoglobulin market. Its projected growth from $2.42 billion in 2024 to $2.59 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%, reflects this trend. The increase in the historic period can be credited to heightened awareness about the risks of rhesus incompatibility, the expansion of national immunization programs, the introduction of maternal and neonatal health policies, an increase in global birth rates, and the rise in blood transfusion procedures.

In the coming years, the anti-D immunoglobulin market is projected to witness robust expansion, anticipating to reach a market value of $3.34 billion by 2029, with a compound annual growth rate (CAGR) of 6.6%. The spur in growth during the forecast period can be ascribed to the growing demand for prenatal and postnatal care, enhanced focus towards maternal health in developing and transition economies, increments in healthcare infrastructure capital, the expansion of global health coverage programs, and regulatory support for immunoglobulin treatment modalities. Key trends that can be seen during the projected period include advancements in plasma segmentation technology, the emergence of recombinant antibody alternatives, growth in automation within immunoglobulin production, the utilization of high-purity formulation methodologies, and the incorporation of cold chain surveillance systems.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25694&type=smp

What Core Drivers Are Expected To Influence The Anti-D Immunoglobulin Market?

The surge in birth rates is anticipated to drive the growth of the anti-D immunoglobulin market. Birth rates, which depict the number of live births per 1,000 individuals annually, are on the rise due to limited access to education and family planning facilities, leading to higher fertility rates and increased family sizes. Anti-D immunoglobulin aids this increase in birth rates by averting Rh incompatibility during pregnancy, mitigating the risk of hemolytic disease in newborns and promoting healthier pregnancy outcomes in the future. As an example, the Centers for Disease Control and Prevention, a government agency based in the US, reported 3,622,673 births in 2024 in April 2025, marking a 1% growth from the preceding year. Thus, the growth in birth rates is a significant contributor to the upswing of the anti-D immunoglobulin market. The growth in healthcare infrastructure, due to better access to maternal care services, is also expected to fuel the growth of the anti-D immunoglobulin market. This infrastructure, which encompasses facilities, equipment, personnel, and supporting structures necessary to deliver healthcare services within a population, is expanding due to a growing global population, subsequently spurring a greater demand for medical care and necessitating the establishment of additional hospitals, clinics, and more. The growth of healthcare infrastructure improves access to maternal care, permitting effective screening and timely administration of anti-D immunoglobulin, thus reducing the risk of hemolytic disease in newborns. For instance, the Department of Health and Social Care, a government organization based in the UK, unveiled plans in May 2023 to invest over $27 billion (£20 billion) in developing new hospital facilities. Under the New Hospital Programme, two hospitals are already operational, five are under construction, and over 20 are projected to be in progress or completed by the end of the following year. Consequently, the growth of healthcare infrastructure is greatly influencing the expansion of the anti-D immunoglobulin market.

What Are The Main Segment Classifications In The Anti-D Immunoglobulin Market?

The anti-d immunoglobulin market covered in this report is segmented –

1) By Product Type: Intramuscular Anti-D Immunoglobulin, Intravenous Anti-D Immunoglobulin

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel

3) By Application: Hemolytic Disease Of The Newborn, Immune Thrombocytopenic Purpura, Antenatal And Postnatal Prophylaxis, Other Applications

4) By End-User: Hospitals, Clinics, Blood Banks, Research Laboratories

Subsegments:

1) By Intramuscular Anti-D Immunoglobulin: Standard Dose, High Dose, Pre-Filled Syringes, Vials

2) By Intravenous Anti-D Immunoglobulin: Lyophilized Powder, Liquid Formulation, Single-Use Vials, Multi-Dose Vials

How Are Industry Trends Steering The Expansion Of The Anti-D Immunoglobulin Market?

Prominent businesses in the anti-D immunoglobulin market are prioritizing the creation of cutting-edge solutions like recombinant anti-D immunoglobulin. The goal is to widen the reach of safe and reliable prophylaxis for Rh-negative pregnant individuals and enhance maternal health outcomes. Recombinant anti-D immunoglobulin is a laboratory-developed monoclonal antibody aimed at preventing Rh incompatibility among Rh-negative people. It offers a superior alternative to plasma-derived anti-D treatments because it boasts improved consistency, safety, and scalability. For example, in January 2022, an Indian biopharmaceutical firm named Bharat Serums and Vaccines (BSV), debuts the world’s first commercially available recombinant anti-Rho (D) immunoglobulin. This product utilizes innovative recombinant technology, boosting the dependability of the product and lessening variability linked with plasma-derived alternatives. This product is particularly noteworthy in areas with high Rh-negative pregnancy rates as it refines preventive healthcare and lowers the possibility of newborns developing hemolytic disease.

Which Companies Are Contributing Significantly To The Anti-D Immunoglobulin Market Growth?

Major companies operating in the anti-d immunoglobulin market are Merck Group, Bayer AG, CSL Behring, Baxter International Inc., Intas Pharmaceuticals Ltd., Octapharma AG, Zydus Lifesciences Limited, Emergent BioSolutions Inc., Kedrion Biopharma Inc., Biotest AG, Sanquin, Taj Pharmaceuticals Limited, Kamada Pharmaceuticals, Bharat Serums and Vaccines Limited, Saol Therapeutics Inc., Aetos Pharma Private Limited, Avin Darou, PV Pharma Healthcare Pvt. Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Ocean Pharmacoat Pvt. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/anti-d-immunoglobulin-global-market-report

Which Region Holds The Greatest Opportunity For Anti-D Immunoglobulin Market Expansion?

North America was the largest region in the anti-D immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-d immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=25694&type=smp

Browse Through More Reports Similar to the Global Anti-D Immunoglobulin Market 2025, By The Business Research Company

Immunotoxin Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immunotoxin-global-market-report

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

Mammalian Polyclonal Immunoglobulin G Igg Antibody Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/mammalian-polyclonal-immunoglobulin-g-igg-antibody-global-market-report

About The Business Research Company:

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model